Regenxbio (RGNX) expects its balance in cash, cash equivalents and marketable securities of $302M as of September 30, 2025 to fund its operations into early 2027. This cash runway guidance is based on the Company’s current operational plans and excludes the impact of any material payments that may potentially be received from partners or licensees upon the achievement of development or regulatory milestones, or upon the approval or commercialization of product candidates, and excludes potential monetization of a PRV that would be received upon potential approval of clemidsogene lanparvovec.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RGNX:
- FDA’s ‘surprising’ uniQure reversal drags down Biohaven
- RegenXBio’s Strong Position in Biotechnology Justifies Buy Rating Amid Gene Therapy Uncertainties
- FDA’s uniQure reversal unlikely to impact Regenxbio’s programs, says Stifel
- Regenxbio completes enrollment in Duchenne trial, begins RGX-202 production
- RegenXBio’s RGX-202 Gene Therapy: A Promising Step for Duchenne Muscular Dystrophy